Severe Acute Malnutrition

VANCOUVER, British Columbia , July 22, 2021 (GLOBE NEWSWIRE) -- AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) is pleased to announce the Company’s RUTF product development premise has been validated. Recent data presented this week on the co-intersection of HIV and nutrition at the 11th International AIDS Society Conference on HIV Science (IAS 2021), held virtually with a hub in Berlin, demonstrates the need for innovation in the universal address of famine, starvation, malnutrition, and food insecurity in the treatment of HIV and AIDS. Two scientific presentations definitively report increased disease progression in patient populations lacking access to efficacious therapeutic nutritional support and show the correlation between this failing and the undermining of antiretroviral therapy to suppress viral reproduction. Patterns of drug resistance occur when malabsorption of therapeutics is accentuated by food insecurity in vulnerable patient populations, which have been successfully addressed by interventions being developed by AREV’s human nutrition product line. Both SUS-TAINN™, an advanced stage Ready-to-Use Therapeutic Food (RUTF), and AREV’s enteral formula are being designed to meet the precise clinical nutritional needs of the patient populations at greatest risk for the development of Serious Acute Malnutrition (SAM). At the IAS Conference on HIV Science, University of Cincinnati and Florida International University researchers presented a study demonstrating that persistent immune activation was associated with chronic food insecurity and malnutrition. Titled “Food insecurity is associated with increased immune activation in people living with HIV”, this study demonstrated compelling data establishing the biological link between malnutrition and chronic disease in HIV populations. The research further showed immune activation remained consistent in relationship to food insecurity, which is characteristic of immune dysfunction in patients challenged by viral infections. In the second poster presented by University of California, San Francisco (UCSF) researchers, Expected impact of malnutrition on first-line antiretroviral drug exposure in a global population of children in countries with highest child mortality: a quantitative modelling and simulation study, data on three antiretrovirals from 30 countries, designated recipient nations by the President’s Emergency Plan for AIDS Relief (PEPFAR), demonstrated underexposure of first-line antiretrovirals is attributable to malnutrition and results in a decline in therapeutic efficacy. Chad Johnson, Esq., member of the IAS, the Infectious Disease Society of America (IDSA), and the European AIDS Clinical Society (EACS), and special counsel to AREV, stated, “This new data demonstrates the clear mandate that more funding for RUTFs for HIV patients in PEPFAR-designated nations experiencing food insecurity is an immediate priority for ensuring effective responses to pandemics that have implications for global stability and security. Leadership at all levels is facing questions of accountability to resolve this heinous circumstance that is predicted by the WHO to account for unprecedented numbers of deaths due to famine.” AREV’s flagship product, SUS-TAINN™, is a competitive, next generation RUTF being designed for patient populations suffering from SAM and starvation, clinically referred to as inanition, as characterized by World Health Organization (WHO) and US Aid for International Development (USAID) during famine and accounts for disease progression and heightened death rates in the millions of people each year. SUS-TAINN will address the clinical need for delivery of enhanced nutrition that addresses both gut permeability and gut microbiome decimation while providing delivery of essential calories and micronutrients that influence the course of predictable disease progression. SUS-TAINN™ is being designed to meet public health procurement requirements for international aid agencies as currently defined by the U.S. Department of Agriculture, World Food Program (WFP), and President's Emergency Plan For AIDS Relief ($50 million grant in 28 designated countries). Dr. Roscoe Moore DVM, MPH, PhD, Former US Assistant Surgeon General (retired), member of the Board of Advisors to the Institute of Human Virology and a Fellow of the Potomac Institute, and Chairman of AREV’s Scientific Advisory Board, commented, “The current disparities in addressing global public health by leading procurement agencies, to ensure that adequate address of human nutrition, requires immediate action to preserve contemporary advances in the treatment of HIV for the most vulnerable of key populations.” Current legislative efforts to address global famine include enhancement of multi-sectoral nutrition strategies that have leveraged more than $18.5 billion in country-level research-driven programs by the U.S. Department of State. Recent United Nations reports demonstrate that greater than 690 million people are severely undernourished, further exacerbated by climate change and the COVID-19 pandemic. WFP Executive Director Davis Beasley has announced that the world will need $4.9 billion to prevent 30 million deaths this calendar year alone due to starvation. Dr. Jay Noller, Professor Emeritus of Agriculture at Oregon State University, and a member of the AREV’s Scientific Advisory Board, observes that “research presented at IAS provides compelling findings that the efficacy of antiretroviral therapies (ART) in a global cohort of young children is only as good as their baseline nutritional status, wherein two-thirds of all children under ART begin their sprint to better health from a hole as deep as their state of malnutrition. Without addressing the nutritional state of those suffering acute malnutrition, HIV therapy may be of no use to them. It is clear to me that we absolutely must create a better means of therapeutically improving the nutritional status of two-thirds of children in the world also suffering from HIV/AIDS.” The IAS Conference on HIV Science is the world’s leading meeting on HIV and AIDS science and clinical studies and generates directions in AIDS policy development that includes access to essential therapeutics for the estimated 36 million people infected with HIV. IAS 2021 includes presentations from leading doctors, scientists, activists and scholars in relevant areas of virology and immunology, and clinical research generated by industry and publicly sponsored research networks around the world. The conference can be found at About AREV NanoTec Brands Inc. AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO). NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FORWARD LOOKING INFORMATION Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s pro . For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit arevlifesciences.com.

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (”AREV” or the “Company”) is pleased to announce it has expanded its extraction results to Clinical Characterization of Compounds and provides this update of corporate developments consistent with its news announcements and AREV’s transformed corporate website now located at . The Company encourages its shareholders and interested parties to review the new website in light of this and recent news releases. In the first five months of 2021, AREV has advanced its core competencies in extraction systems, functional ingredient production, and natural product formulations, expanding its know-how into innovative plant compound identification and medicinal characterization for utility in the Company’s development of advanced-stage nutritional foods and discovery of plant-based drugs (or phytomedicinalization). Working with noted experts recruited to AREV’s leadership and Scientific Advisory Board (SAB), AREV’s corporate team has also initiated collaborations and significant negotiations with third-party academic and business partners to enhance its participation in programs involving preclinical, clinical, and U.S. FDA-approved drugs. Mike Withrow, AREV CEO, said, “AREV is becoming a fully integrated early-stage life sciences enterprise. I am pleased that AREV’s pursuit of its prior business model created the valuable shareholder opportunity on which the Company is quickly executing, from enhancement of AREV’s extraction innovations to its proprietary initiatives with the characterization of therapeutic compounds found in sea cucumber, Moringa, and other natural sources. AREV is in a substantial growth stage through its advancement of creative collaborations with the advice of its high-level appointments to the Company’s Scientific Advisory Board.” AREV is invested in phytomedicinal discoveries of broad spectrum antivirals and has made significant commitments to human nutrition in areas of unmet need in strategic markets, including the development of an advanced-stage Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM), branded as SUS-TAINN, and an Enteral Formula, RES-TORE. Through our SAB and our development of collaborations, with Voynich Biosciences, Inc. and Oyagen, AREV is connected to the Linus Pauling Institute at Oregon State University (OSU). AREV is engaging scientists to characterize compounds for its proprietary ingredients while building AREV’s team of preclinical drug discovery partners in the Company’s rational drug design, driven by molecular epidemiology. “Our strategy is dedicated to generating revenue to support drug development both through novel therapeutic approaches to human nutrition in contexts of malnutrition and pandemic disease and through development of enhanced OTC products with validated claims developed with advanced, scientifically-characterized ingredients,” said Roscoe M. Moore, Jr., DVM, MPH, PHD, Assistant U.S. Surgeon General (retired), Chairman of AREV’s SAB. On the second of these revenue strategies, through the recently announced collaboration with GVB Biopharma, AREV is preparing to launch two soft gel products containing proprietary, characterized ingredients derived from sea cucumber and hops infused with CBD. For further information, contact Mike Withrow, news@arevlifesciences.com 778-929-6536. For more information visit arevlifesciences.com. On behalf of the Board, Mike WithrowCEO & Director